Sugi Predict

Sugi Predict / Compounds / Fluralaner

Fluralaner

Fluralaner

SCHEMBL8513367

Cc1cc(C2=NO[C@@](c3cc(Cl)cc(Cl)c3)(C(F)(F)F)C2)ccc1C(=O)NCC(=O)NCC(F)(F)F

nearest known ligand 0.35

Full drug profile on Sugi Atlas →

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ CA1 P00915 1/20 0.32
▸ CA2 P00918 1/20 0.32
▸ PTGES O14684 1/20 0.32
▸ HDAC4 P56524 1/20 0.31
▸ ORAI1 Q96D31 4/20 0.31
▸ GABRA5 P31644 1/20 0.31
▸ LMNA P02545 1/20 0.31
▸ MEN1 O00255 1/20 0.30
▸ KMT2A Q03164 1/20 0.30
▸ TDP1 Q9NUW8 1/20 0.30
▸ CYP1A2 P05177 1/20 0.30
▸ CYP2D6 P10635 1/20 0.30
▸ CYP2C9 P11712 1/20 0.30
▸ CYP2C19 P33261 1/20 0.30
▸ KDM4E B2RXH2 1/20 0.30
▸ ELOVL6 Q9H5J4 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Fluralaner SCHEMBL29362559 1.00 CA1 (0.32) CA1CA2PTGESHDAC4ORAI1
Fluralaner SCHEMBL29399660 1.00 CA1 (0.32) CA1CA2PTGESHDAC4ORAI1
Fluralaner SCHEMBL8515337 1.00 CA1 (0.32) CA1CA2PTGESHDAC4ORAI1
Fluralaner SCHEMBL121934 1.00 CA1 (0.32) CA1CA2PTGESHDAC4ORAI1
SCHEMBL23546689 0.95 GABRA5 (0.31) CA1CA2PTGESGABRA5
SCHEMBL22919822 0.94 PTGES (0.33) PTGESHDAC4KDM4E
SCHEMBL120084 0.94 PTGES (0.33) PTGESHDAC4KDM4E
SCHEMBL15999841 0.94 PTGES (0.31) CA1CA2PTGESGABRA5LMNA
SCHEMBL119374 0.94 PTGES (0.35) CA1CA2PTGESORAI1GABRA5
SCHEMBL23530405 0.93 LMNA (0.32) CA1CA2PTGESORAI1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11548859-B2 Method for producing (5,S)-4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4Hisoxazol-3-yl]-2-methyl-benzoic acid INTERVET INC. (US) 2023-01-10 — — US claimed
US-20220073479-A1 Method for Producing (5,S)-4-[5-(3,5-Dichlorophenyl)-5-(Trifluoromethyl)-4Hisoxazol-3-YL]-2-Methyl-Benzoic Acid INTERVET INC. (US) 2022-03-10 — — US claimed
CN-113242854-A Preparation method of (5S) -4- [5- (3, 5-dichlorophenyl) -5- (trifluoromethyl) -4H-isoxazol-3-yl ] -2-methylbenzoic acid 英特维特国际股份有限公司 2021-08-10 — — CN claimed
CN-113227060-A Preparation method of (5S) -4- [5- (3, 5-dichlorophenyl) -5- (trifluoromethyl) -4H-isoxazol-3-yl ] -2-methylbenzoic acid 英特维特国际股份有限公司 2021-08-06 — — CN claimed
US-9062010-B2 Crystalline polymorphs of isoxazoline compound and production method thereof NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2015-06-23 — — US claimed
US-20150005507-A1 CRYSTALLINE POLYMORPHS OF ISOXAZOLINE COMPOUND AND PRODUCTION METHOD THEREOF NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2015-01-01 — — US claimed
US-20250287955-A1 METHODS OF PROTECTING A PLANT FROM INSECT PESTS Novonesis Plant Biosolutions A/S (DK) 2025-09-18 — — US disclosed
JP-2024167399-A Method for preparing (5S)-4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4H-isoxazol-3-yl]-2-methyl-benzoic acid インターベット インターナショナル ベー． フェー． 2024-12-03 — — JP disclosed
EP-3898598-B1 METHOD FOR PRODUCING (5S)-4-[5-(3,5-DICHLOROPHENYL)-5-(TRIFLUOROMETHYL)-4H-ISOXAZOL-3-YL]-2-METHYL-BENZOIC ACID INTERVET INT BV (NL) 2024-09-11 — — EP disclosed
US-20240239759-A1 ISOXAZOLINE COMPOSITIONS AND THEIR USE AS ANTIPARASITICS INTERVET INC. (US) 2024-07-18 — — US disclosed
EP-4076447-B1 PARASITE CONTROL IN RUMINANTS INTERVET INT BV (NL) 2024-01-17 — — EP disclosed
US-11548859-B2 Method for producing (5,S)-4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4Hisoxazol-3-yl]-2-methyl-benzoic acid INTERVET INC. (US) 2023-01-10 — — US disclosed
US-11548859-B2 Method for producing (5,S)-4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4Hisoxazol-3-yl]-2-methyl-benzoic acid INTERVET INC. (US) 2023-01-10 — — US disclosed
WO-2013139822-A1 NOVEL BISOXIME MICROBIOCIDES SYNGENTA PARTICIPATIONS AG (CH) 2013-09-26 — — WO disclosed
EP-2641901-A1 Novel microbiocides Syngenta Participations AG. (CH) 2013-09-25 — — EP disclosed
WO-2013092460-A1 CYCLIC BISOXIME MICROBICIDES SYNGENTA PARTICIPATIONS AG (CH) 2013-06-27 — — WO disclosed
WO-2013026900-A1 PYRIDINE DERIVATIVES AS MICROBIOCIDES SYNGENTA PARTICIPATIONS AG (CH) 2013-02-28 — — WO disclosed
WO-2012175474-A1 1,2,3 TRIAZOLE PESTICIDES SYNGENTA PARTICIPATIONS AG (CH) 2012-12-27 — — WO disclosed
WO-2012117021-A2 NOVEL MICROBIOCIDAL OXIME ETHERS SYNGENTA PARTICIPATIONS AG (CH) 2012-09-07 — — WO disclosed
WO-2012069601-A1 SUBSTITUTED QUINAZOLINES AS FUNGICIDES SYNGENTA PARTICIPATIONS AG (CH) 2012-05-31 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220073479-A1 Method for Producing (5,S)-4-[5-(3,5-Dichlorophenyl)-5-(Trifluoromethyl)-4Hisoxazol-3-YL]-2-Methyl-Benzoic Acid KDM5A, GABRA5, KDM5B CA1 1539/4885CA2 613/4885PTGES 1120/4885
US-11548859-B2 Method for producing (5,S)-4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4Hisoxazol-3-yl]-2-methyl-benzoic acid GABRA5, KDM5A, KDM5B CA1 1342/4885CA2 531/4885PTGES 1179/4885
US-20240239759-A1 ISOXAZOLINE COMPOSITIONS AND THEIR USE AS ANTIPARASITICS PRDX5, TUBA3C, TUBA1C CA1 1771/4885CA2 651/4885PTGES 2115/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.